HBV-IN-23

• UNSPSC Description:

  HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis[1].

• Target Antigen:

  Apoptosis; DNA/RNA Synthesis; HBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/hbv-in-23.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CN(CCCOC1=CC=C2N=C(N(C(C2=C1)=O)CC3=CC=CO3)SCC4=CC=CC=C4)C

• Molecular Weight:

  449.57

• References & Citations:

  [1]Qiu J, et al. Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. Eur J Med Chem. 2020 Nov 1;205:112581.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2413649-89-3